NOV 06, 2020 3:30 PM PST

Anti-depressant Shows Promise in Treating Childhood Cancer

WRITTEN BY: Annie Lennon

Researchers from Sweden and the US have found that a commonly prescribed antidepressant may help stop the growth of a cancer known as childhood sarcoma, a disease in which cancer cells form in soft tissues of the body. 

In their study, the researchers looked at commonalities between two large groups of cell surface receptors. The first is known as G protein-coupled receptors (GPCRs) and is targeted by more than half of all developed drugs to treat conditions including allergies, depression, and hypertension. Until now, however, they have not been targeted to treat cancer. 

The second group of cell surface receptors is known as receptor tyrosine kinases (RTKs). These receptors are currently targeted by drugs to treat various cancers, including breast and colon cancer, due to their involvement in a variety of cellular abnormalities. One receptor in this group, known as a insulin-like growth factor receptor (IGF1R), is known to play a key role in a variety of cancers. While some have attempted to use it as a drug target, none have so far succeeded.

In this study, however, the researchers found that IGF1R shares a signaling module with GPCRs. This means that drugs that target GCPRs may be able to affect its function. As such, the researchers decided to repurpose an existing drug to see how it may affect cancer growth. 

In the end, they decided to treat mice infected with childhood sarcoma cells with Paroxetine, an antidepressant that impairs a serotonin reuptake receptor that is a part of the GPCR-family. In doing so, they found that the drug was able to reduce the number of IGF1R receptor cells on the malignant cells, and thus suppress tumor growth. 

"We have developed a novel strategy to control the activity of these tumor-driving receptors by striking the GPCRs," says Leonard Girnita, principal investigator of the study. 

"To our knowledge this represents a new paradigm for the entire class of cancer-relevant RTKs and could be used as a starting point for the rational design of specific therapeutics in virtually any pathological conditions. This is especially important considering the huge number of GPCR-targeting medicines already in clinical use and with low toxicity."

The researchers now hope to develop their strategy to selectively cross-target multiple RTKs to treat cancer. They then hope to test their findings in clinical trials. 

 

Sources: Medical XpressCancer Research

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
OCT 14, 2021
Cancer
Mechanism of Resistance to Colorectal Cancer Treatment Uncovered
OCT 14, 2021
Mechanism of Resistance to Colorectal Cancer Treatment Uncovered
Colorectal cancer develops when a series of changes occur across multiple genes.  While researchers have paid signi ...
OCT 26, 2021
Microbiology
A Strategy to Improve the Efficacy of Antibiotics
OCT 26, 2021
A Strategy to Improve the Efficacy of Antibiotics
For many years, scientists and experts have warned about a building crisis - antibiotics are becoming less reliable, bac ...
OCT 29, 2021
Drug Discovery & Development
A novel analogue of psilocin to treat mental health disorders
OCT 29, 2021
A novel analogue of psilocin to treat mental health disorders
Psilocybin and its metabolite psilocin are naturally occurring compounds that are commonly found in some genus of mushro ...
NOV 17, 2021
Drug Discovery & Development
Native American Plant Extract Treats Pain and Diarrhea
NOV 17, 2021
Native American Plant Extract Treats Pain and Diarrhea
Plants with a long history of use as topical analgesics by Native Americans may also be helpful against diarrhea. The co ...
NOV 30, 2021
Drug Discovery & Development
Enabling new levels of quantification with the SCIEX 7500 system - powered by SCIEX OS Software
NOV 30, 2021
Enabling new levels of quantification with the SCIEX 7500 system - powered by SCIEX OS Software
Sensitivity is a fundamental performance characteristic of a mass spectrometer The SCIEX 7500 system is enabling new lev ...
NOV 24, 2021
Drug Discovery & Development
A prescription digital therapeutic to treat alcohol use disorders
NOV 24, 2021
A prescription digital therapeutic to treat alcohol use disorders
Can a software application be used treat alcohol use disorders? The medical technology company Pear Therapeutics is ...
Loading Comments...